All In Biotech

Drug Trial Radar · NCT06165341

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 1, 2024

Primary completion

Aug 26, 2028

Study completion Aug 26, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver. People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study. After their last clinic visits, participants will have two choices: 1. They can complete this study and return to the clinic 3 and 6 months later so the study doctors can check for side effects; OR 2. If they meet the rules, they can join another study (called extension or continuation study), in which they will receive fazirsiran every 3 months and will continue to have health checks.

Conditions

  • Alpha1-Antitrypsin Deficiency

Interventions

  • Fazirsiran InjectionDrug

    Fazirsiran will be injected subcutaneously.

  • PlaceboDrug

    Fazirsiran matching placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From start of study drug administration up to end of study (EOS) (Week 124)
  2. Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function ParametersTime frame: From start of study drug administration up to EOS (Week 124)
  3. Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung DensitometryTime frame: Baseline up to Week 100
  4. Number of Participants With Clinically Significant Changes in Vital SignsTime frame: From start of study drug administration up to EOS (Week 124)
  5. Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) ParametersTime frame: From start of study drug administration up to EOS (Week 124)
  6. Number of Participants With Clinically Significant Changes in Clinical Laboratory ParametersTime frame: From start of study drug administration up to EOS (Week 124)

Locations

41 sites in 13 countries. Site status is shown where the registry gives one.

  • St Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • Mayo Clinic - PPDS

    Phoenix, Arizona · Recruiting

  • University of Arizona Thomas D. Boyer Liver Institute

    Tucson, Arizona · Recruiting

  • University of California San Diego

    La Jolla, California · Recruiting

  • UCLA Pulmonary and Critical Care

    Los Angeles, California · Recruiting

  • University of California Benioff Children's Hospital

    San Francisco, California · Recruiting

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado · Recruiting

  • Schiff Center for Liver Diseases/University of Miami

    Miami, Florida · Recruiting

  • Indiana University School of Medicine-Indianapolis

    Indianapolis, Indiana · Recruiting

  • University Of Iowa Hospitals And Clinics

    Iowa City, Iowa · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • University of Michigan Hospital - 1500 E Medical Center Dr

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Health System

    Novi, Michigan · Recruiting

  • Mayo Clinic PPDS

    Rochester, Minnesota · Recruiting

  • NYU Langone Medical Center

    New York, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Texas Liver Institute American Research Corporation

    San Antonio, Texas · Recruiting

  • Bon Secours St. Mary's Hospital

    Newport, Virginia · Recruiting

  • LKH-Universitätsklinikum Graz

    Graz, Austria · Recruiting

  • KABEG - Klinikum Klagenfurt Am Wörthersee

    Klagenfurt, Austria · Recruiting

  • UZ Antwerpen

    Antwerp, Belgium · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Inspiration Research Limited

    Toronto, Ontario, Canada · Recruiting

  • Hôpital de La Croix Rousse

    Lyon, France · Recruiting

  • Hopital PONTCHAILLOU CHU de Rennes

    Rennes, France · Recruiting

  • Hôpital Paul Brousse

    Val-de-Marne, France · Recruiting

  • Universitätsklinikum der RWTH Aachen

    Aachen, Germany · Recruiting

  • Charité - Campus Virchow-Klinikum

    Berlin, Germany · Recruiting

  • Hannover Medical School

    Hanover, Germany · Recruiting

  • Universitätsklinikum Tübingen

    Tübingen, Germany · Recruiting

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy · Recruiting

  • ID Clinic Arkadiusz Pisula

    Mysłowice, Poland · Withdrawn

  • CCA Hospital Braga

    Braga, Portugal · Recruiting

  • Hospital Dr. Nélio Mendonça

    Funchal, Portugal · Recruiting

  • Centro Hospitalar de Universitário de Santo António E.P.E

    Porto, Portugal · Recruiting

  • Hospital Universitario Virgen del Rocio - PPDS

    Seville, Spain · Recruiting

  • Karolinska Universitetssjukhuset Huddinge

    Huddinge, Sweden · Recruiting

  • Universitätsspital Bern

    Bern, Switzerland · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.